EX-10.1(A) 2 d344523dex101a.htm RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT Execution VersionResearch and Development Collaboration, Option, and License Agreement • May 5th, 2020 • Delaware
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN SMITHKLINE BEECHAM CORPORATION D/B/A GLAXOSMITHKLINE and ANACOR PHARMACEUTICALS, INC.Research and Development Collaboration, Option and License Agreement • October 26th, 2010 • Anacor Pharmaceuticals Inc • Pharmaceutical preparations • New York
This RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into and made effective as of the 5th day of October, 2007 (the "Effective Date") by and between Anacor Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 1060 East Meadow Circle, Palo Alto, CA 94303 ("Anacor"), and SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a Pennsylvania corporation having offices at One Franklin Plaza, Philadelphia, PA 19101 ("GSK"). Anacor and GSK are each referred to herein by name or as a "Party" or, collectively, as "Parties."
AMENDMENT NO. 1 TO THE RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENTResearch and Development Collaboration, Option, and License Agreement • July 5th, 2012 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT NO. 1 TO THE RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENT (the “Amendment No. 1”) is made this 28th day of July, 2011 (the “Amendment No. 1 Effective Date”) by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”) and GlaxoSmithKline LLC, a Delaware limited liability company with a principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19102, United States of America (formerly known as SmithKline Beecham Corporation) (“GSK”). OncoMed and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MASTER AMENDMENT TO RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENTResearch and Development Collaboration, Option and License Agreement • November 14th, 2011 • Anacor Pharmaceuticals Inc • Pharmaceutical preparations • New York
This MASTER AMENDMENT TO RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Amendment”) is entered into and made effective as of the 2nd day of September, 2011 (the “Amendment Effective Date”) by and between Anacor Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 1020 East Meadow Circle, Palo Alto, CA 94303 (“Anacor”), and GlaxoSmithKline, LLC (formerly known as SmithKline Beecham Corporation), a Delaware Limited Liability company having offices at One Franklin Plaza, Philadelphia, PA 19101 (“GSK”).
RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN SMITHKLINE BEECHAM CORPORATION D/B/A GLAXOSMITHKLINE and ANACOR PHARMACEUTICALS, INC.Research and Development Collaboration, Option and License Agreement • November 3rd, 2010 • Anacor Pharmaceuticals Inc • Pharmaceutical preparations • New York
This RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into and made effective as of the 5th day of October, 2007 (the "Effective Date") by and between Anacor Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 1060 East Meadow Circle, Palo Alto, CA 94303 ("Anacor"), and SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a Pennsylvania corporation having offices at One Franklin Plaza, Philadelphia, PA 19101 ("GSK"). Anacor and GSK are each referred to herein by name or as a "Party" or, collectively, as "Parties."
RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEENResearch and Development Collaboration, Option and License Agreement • October 9th, 2007 • Anacor Pharmaceuticals Inc • Pharmaceutical preparations • New York
This RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of the 5th day of October, 2007 (the “Effective Date”) by and between Anacor Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 1060 East Meadow Circle, Palo Alto, CA 94303 (“Anacor”), and SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a Pennsylvania corporation having offices at One Franklin Plaza, Philadelphia, PA 19101 (“GSK”). Anacor and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
